Tejas Patil/X
Nov 25, 2024, 17:49
Tejas Patil: Why biomarkers like PDL1 and TMB aren’t always associated with ‘hot’ or ‘cold’ immune TME
Tejas Patil, Thoracic oncologist CU Cancer Center, shared a post by Cancer Cell on X:
“Nice article that gets into why biomarkers like PDL1 and TMB aren’t always associated with ‘hot’ or ‘cold’ immune TME.”
Quoting Cancer Cell’s post:
“Online Now: Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.”
Authors: David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry, Emmanuel S. Antonarakis, Stephanie L. Graff, Michael J. Hall, Hossein Borghaei, Dave S.B. Hoon, Stephen V. Liu, Patrick C. Ma, Rana R. McKay, Trisha Wise-Draper, John Marshall, George W. Sledge, David Spetzler, Hao Zhu
Andreas Seeber
Andrew Elliott
biomarkers
cancer
Cancer Cell
Dave S B Hoon
David Hsiehchen
David Spetzler
Emmanuel S Antonarakis
George W. Sledge
Hao Zhu
Hossein Borghaei
immune cell infiltration
Joanne Xiu
John Marshall
lymphoid activation
Michael J Hall
OncoDaily
Oncology
Patrick C. Ma
Rana R. McKay
Stephanie L. Graff
Stephen V Liu
Tejas Patil
Trisha Wise-Draper
Wafik El-Deiry
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 22:37
Sep 2, 2025, 22:03
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54